Prevention of the cryptic epitope SLAYGLR within osteopontin does not influence susceptibility to Candida albicans infection.
The effect of an antiosteopontin antibody (M5 Ab) reacting with the SLAYGLR sequence within osteopontin on the host susceptibility to infection was investigated in a murine model of disseminated candidiasis. The treatment with anti-tumor necrosis factor alpha antibody enhanced fungal infection, while the treatment with M5 Ab did not affect the infection.
Sato
Ikuko
I
Fermentation Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan. ikuko.sato@jp.astellas.com
Yamamoto
Nobuchika
N
Yamazaki
Harumi
H
Hashimoto
Seiji
S
Hino
Motohiro
M
Sakai
Fumihiko
F
Fujie
Akihiko
A
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002176:Candida albicans / Q000472:pathogenicity*; D002177:Candidiasis / Q000276:immunology / Q000382:microbiology / Q000503:physiopathology / Q000628:therapy*; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D000939:Epitopes / Q000276:immunology*; D005260:Female; D006801:Humans; D007668:Kidney / Q000382:microbiology; D051379:Mice; D008813:Mice, Inbred ICR; D053495:Osteopontin; D012795:Sialoglycoproteins / Q000737:chemistry* / Q000276:immunology*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D000939:Epitopes; C506895:SPP1 protein, human; D012795:Sialoglycoproteins; C506896:Spp1 protein, mouse; D014409:Tumor Necrosis Factor-alpha; D053495:Osteopontin